Contemporary radiotherapy: present and future

RA Chandra, FK Keane, FEM Voncken, CR Thomas - The Lancet, 2021 - thelancet.com
Oncology care is increasingly a multidisciplinary endeavour, and radiation therapy
continues to have a key role across the disease spectrum in nearly every cancer. However …

Radiation-induced lung injury: assessment and management

AN Hanania, W Mainwaring, YT Ghebre, NA Hanania… - Chest, 2019 - Elsevier
Radiation-induced lung injury (RILI) encompasses any lung toxicity induced by radiation
therapy (RT) and manifests acutely as radiation pneumonitis and chronically as radiation …

Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified …

JY Chang, RJ Mehran, L Feng, V Verma, Z Liao… - The Lancet …, 2021 - thelancet.com
Background A previous pooled analysis of the STARS and ROSEL trials showed higher
survival after stereotactic ablative radiotherapy (SABR) than with surgery for operable early …

Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an …

JY Chang, SH Lin, W Dong, Z Liao, SJ Gandhi, CM Gay… - The Lancet, 2023 - thelancet.com
Background Stereotactic ablative radiotherapy (SABR) is the standard treatment for
medically inoperable early-stage non-small-cell lung cancer (NSCLC), but regional or …

Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised …

D Ball, GT Mai, S Vinod, S Babington, J Ruben… - The Lancet …, 2019 - thelancet.com
Background Stereotactic ablative body radiotherapy (SABR) is widely used to treat
inoperable stage 1 non-small-cell lung cancer (NSCLC), despite the absence of prospective …

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

PE Postmus, KM Kerr, M Oudkerk, S Senan… - Annals of …, 2017 - annalsofoncology.org
Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …

Electrochemical biosensors for the detection of lung cancer biomarkers: A review

A Khanmohammadi, A Aghaie, E Vahedi, A Qazvini… - Talanta, 2020 - Elsevier
Cancer is one of the most widespread challenges and important diseases, which has the
highest mortality rate. Lung cancer is the most common type of cancer, so that about 25% of …

Radiotherapy treatment for lung cancer: Current status and future directions

SK Vinod, E Hau - Respirology, 2020 - Wiley Online Library
Radiotherapy is an important modality used for the treatment of lung cancer. Seventy‐seven
percent of all patients with lung cancer have an evidence‐based indication for radiotherapy …

Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians

WA Hall, E Paulson, XA Li, B Erickson… - CA: a cancer journal …, 2022 - Wiley Online Library
Radiation therapy (RT) continues to play an important role in the treatment of cancer.
Adaptive RT (ART) is a novel method through which RT treatments are evolving. With the …

Recent developments in radiotherapy

DE Citrin - New England journal of medicine, 2017 - Mass Medical Soc
Recent Developments in Radiotherapy | New England Journal of Medicine Skip to main content
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …